"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL — Stella

Recruiting

Back to NKTCL trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

China

Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan

Key details

Phase

First-in-human testing / Safety & dosing

Sponsor

Mingzhi Zhang

Enrollment target

~50 participants

Started

September 2024

Primary completion

December 2026

Age range

18 Years – 70 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov